Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.

Thumbnail
View/Open
Published version (945.4Kb)
Date
2022-02-28
ICR Author
Huang, Paul
Jones, Robin
Author
Kerrison, WGJ
Lee, ATJ
Thway, K
Jones, RL
Huang, PH
Type
Journal Article
Metadata
Show full item record
Abstract
Immunotherapy in soft tissue sarcoma (STS) has experienced a surge of interest in the past decade, contributing to an expanding number of therapeutic options for this extremely heterogenous group of rare malignancies. Immune checkpoint inhibitors (CPIs) targeting the PD-1 and CTLA-4 axes have demonstrated promising responses in a select number of STS subtypes, including rarer subtypes, such as alveolar soft part sarcoma, SWI/SNF-deficient sarcomas, clear cell sarcoma, and angiosarcoma. Multiple pan-subtype sarcoma trials have facilitated the study of possible predictive biomarkers of the CPI response. It has also become apparent that certain therapies, when combined with CPIs, can enhance response rates, although the specific mechanisms of this possible synergy remain unconfirmed in STS. In addition to CPIs, several other immune targeting agents, including anti-tumour-associated macrophage and antigen-directed therapies, are now under assessment in STS with promising efficacy in some subtypes. In this article, we review the state of the art in immunotherapy in STS, highlighting the pre-clinical and clinical data available for this promising therapeutic strategy.
URI
https://repository.icr.ac.uk/handle/internal/5145
DOI
https://doi.org/10.3390/biomedicines10030573
Collections
  • Clinical Studies
  • Molecular Pathology
Research team
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology
Language
eng
Date accepted
2022-02-24
License start date
2022-02-28
Citation
Biomedicines, 2022, 10 (3), pp. 573 - ?

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.